Articles from nChroma Bio

nChroma Bio, a genetic medicines company advancing in vivo delivery of innovative cargoes to overcome the limitations of existing therapies, today announced new preclinical data presented at The Liver Meeting® 2025 of the American Association for the Study of Liver Diseases (AASLD). The results, including a Poster of Distinction, highlight the potential of the company’s lead candidate, CRMA-1001, to deliver a functional cure for chronic hepatitis B virus (HBV) through a novel epigenetic silencing approach.

nChroma Bio (“nChroma”), a genetic medicines company advancing in vivo delivery of innovative cargoes to overcome the limitations of existing therapies, today announced the acceptance of three abstracts, including a poster of distinction, at the upcoming AASLD Liver Meeting®, taking place November 7 to 11, 2025, in Washington, D.C.

nChroma Bio (“nChroma”), a genetic medicines company advancing programmable in vivo delivery to overcome the limitations of existing therapies, today announced the acceptance of three abstracts, one for oral presentation and two for poster presentations, at the upcoming 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), taking place at the New Orleans Ernest N. Morial Convention Center in New Orleans, LA, and virtually from May 13-17, 2025.

Chroma Medicine and Nvelop Therapeutics today announced their merger and subsequent launch of nChroma Bio (“nChroma” or “the company”) to redefine the future of genetic medicines. nChroma brings together potent epigenetic editing plus non-viral, programmable delivery to address key limitations in the field and expand the scope of treatable diseases. The merger results in an industry-leading company with a deeply experienced team. Jeff Walsh will serve as nChroma’s CEO and Jeff Marrazzo will serve as nChroma’s Chairman of the Board.